'' Radium-223 is the first targeted alpha therapy approved for castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. In Japan, Radium-223 was approved as a treatment for CRPC with bone metastasis in March 2016 based on the results ...'

''To date, more than 700 cases of SPTs have been reported in English literature. About 15% are known to present metastasis or recurrence. However, based on the conventional histopathology, it has been difficult to establish the criteria which could be ...'